Brandes Investment Partners LP reduced its holdings in shares of Amdocs Limited (NASDAQ:DOX - Free Report) by 2.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,279,645 shares of the technology company's stock after selling 60,793 shares during the quarter. Amdocs accounts for 2.2% of Brandes Investment Partners LP's portfolio, making the stock its 8th largest position. Brandes Investment Partners LP owned about 2.02% of Amdocs worth $194,089,000 as of its most recent SEC filing.
Several other institutional investors also recently bought and sold shares of the business. Ironwood Investment Counsel LLC grew its stake in Amdocs by 5.1% during the fourth quarter. Ironwood Investment Counsel LLC now owns 9,357 shares of the technology company's stock worth $797,000 after buying an additional 454 shares during the period. Hilton Capital Management LLC grew its stake in Amdocs by 4.6% during the fourth quarter. Hilton Capital Management LLC now owns 17,602 shares of the technology company's stock worth $1,499,000 after buying an additional 769 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its stake in Amdocs by 280.9% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 126,748 shares of the technology company's stock worth $10,791,000 after buying an additional 93,471 shares during the period. Farther Finance Advisors LLC boosted its stake in shares of Amdocs by 127.9% in the fourth quarter. Farther Finance Advisors LLC now owns 841 shares of the technology company's stock valued at $72,000 after purchasing an additional 472 shares during the period. Finally, HighTower Advisors LLC boosted its stake in shares of Amdocs by 20.0% in the fourth quarter. HighTower Advisors LLC now owns 15,374 shares of the technology company's stock valued at $1,309,000 after purchasing an additional 2,561 shares during the period. 92.02% of the stock is currently owned by hedge funds and other institutional investors.
Amdocs Stock Down 0.1 %
NASDAQ DOX traded down $0.09 during trading hours on Wednesday, reaching $89.19. 594,201 shares of the company traded hands, compared to its average volume of 649,651. Amdocs Limited has a 12 month low of $74.41 and a 12 month high of $93.34. The company has a current ratio of 1.16, a quick ratio of 1.20 and a debt-to-equity ratio of 0.22. The stock has a market capitalization of $10.07 billion, a PE ratio of 20.69, a PEG ratio of 1.47 and a beta of 0.68. The company has a 50 day moving average of $86.90 and a two-hundred day moving average of $87.12.
Amdocs (NASDAQ:DOX - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The technology company reported $1.45 EPS for the quarter, missing analysts' consensus estimates of $1.64 by ($0.19). Amdocs had a net margin of 10.19% and a return on equity of 18.89%. As a group, equities analysts expect that Amdocs Limited will post 6.21 earnings per share for the current year.
Amdocs Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.527 per share. This represents a $2.11 dividend on an annualized basis and a yield of 2.36%. This is an increase from Amdocs's previous quarterly dividend of $0.48. The ex-dividend date of this dividend is Monday, March 31st. Amdocs's dividend payout ratio is 48.72%.
Analysts Set New Price Targets
Separately, StockNews.com downgraded shares of Amdocs from a "strong-buy" rating to a "buy" rating in a research note on Friday, February 28th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $101.20.
Get Our Latest Analysis on Amdocs
Amdocs Company Profile
(
Free Report)
Amdocs Limited, through its subsidiaries, provides software and services worldwide. It designs, develops, operates, implements, supports, and markets open and modular cloud portfolio. The company provides CES23, a 5G and cloud-native microservices-based market-leading customer experience suite, that enables service providers to build, deliver, and monetize advanced services; Amdocs Subscription Marketplace, a software-as-a-service-based platform that includes an expansive network of pre-integrated digital services, such as media, gaming, eLearning, sports, and retail to security and business services; the monetization suite for charging, billing, policy, and revenue management; Intelligent networking suite with a set of modular, flexible, and open service lifecycle management capabilities for network automation journeys; amAIz, a telco GenAI framework; Amdocs Digital Brands Suite, a pre-integrated digital business suite; and Amdocs eSIM Cloud for service providers.
Further Reading
Before you consider Amdocs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amdocs wasn't on the list.
While Amdocs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
